Primary Mediastinal Large B Cell Lymphoma

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Study of SGR-1505 in Mature B-Cell Neoplasms

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity

A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL